Citable filing context

A filing events and research context

Server-rendered

A's research view summarizes recent SEC filing context, starting with mda_quarterly from Jun 1, 2026.

A filing events and research context
FiledItemContext
Jun 1, 2026mda_quarterlyAgilent Technologies reported net revenue of $3.633 billion for the six months ended April 30, 2026, an 8% increase year-over-year, with net income rising to $644 million. Growth was broad across segments, led by Applied Markets (up 10%) and Life Sciences and Diagnostics Markets (up 8%). Key drivers included liquid chromatography, spectroscopy, and the Agilent Advanced Therapeutics CDMO business, with particular strength in pharmaceutical, chemical, and advanced materials markets, offsetting declines in academia and government spending. The company is expanding its Life Sciences and Diagnostics portfolio through the pending $950 million cash acquisition of Biocare. To enhance operating margins, Agilent is executing a restructuring plan targeting $90 million to $95 million in annual cost reductions. Financial risks include inflationary pressures from Middle East geopolitical tensions and evolving trade dynamics, though the company is seeking refunds for IEEPA tariffs following a Supreme Court invalidation. Capital expenditures are projected at $450 million for the year, primarily to expand advanced therapeutics manufacturing capacity in Frederick, Colorado. Shareholder returns remain a priority, evidenced by a $2 billion share repurchase program and consistent quarterly dividends.
Mar 3, 2026mda_quarterlyAgilent Technologies reported net revenue of $1.798 billion for the quarter ended January 31, 2026, a 7% increase year-over-year, though net income declined to $305 million. Growth was distributed across all segments, led by Agilent CrossLab (+9%) through strong demand for repair, maintenance, and consumables. Life Sciences and Diagnostics Markets grew 5%, driven by the BIOVECTRA CDMO business, liquid chromatography, and pathology solutions, while Applied Markets grew 7%, primarily in the chemicals and advanced materials sectors. Operating margin contracted by 3 percentage points to 19.7%, pressured by increased tariffs, restructuring expenses, and higher corporate infrastructure costs. To protect margins, the company is implementing supply chain optimization and targeted pricing. Additionally, the FY25 restructuring plan targets $90 million to $95 million in annual cost reductions. Capital expenditures are projected at $500 million for the fiscal year, centered on expanding nucleic acid therapeutics manufacturing capacity in Frederick, Colorado. Cash provided by operations decreased to $268 million. The company remains active in returning capital, spending $152 million on share repurchases under its $2 billion authorization and paying quarterly dividends of $0.255 per share.
Dec 22, 2025mdaAgilent Technologies reported 2025 net revenue of $6.95 billion, a 7% increase over 2024, with net income reaching $1.3 billion. Growth was primarily driven by the Life Sciences and Diagnostics Markets segment, which rose 11% due to the BIOVECTRA acquisition and strong demand for liquid chromatography and LC-MS in the pharmaceutical market. The Agilent CrossLab segment grew 6%, supported by consumables and repair services, while Applied Markets grew 1%, as food and pharma gains were offset by declines in academic and government spending. Total gross margin declined 200 basis points to 52.4%, pressured by higher tariffs, shipping costs, and an unfavorable product mix, including lower margins from the specialty CDMO business. Management expects to mitigate tariff impacts in 2026 through pricing and supply chain optimization. Capital expenditures are projected at $500 million for 2026, focused on expanding nucleic acid therapeutic manufacturing in Frederick, Colorado. The company is implementing a restructuring plan to reduce annual costs by $75 million to $80 million. Liquidity remains robust, with $1.79 billion in cash and $1.9 billion remaining under its 2024 share repurchase program.

Source: SEC EDGAR filing text and events; period Jun 1, 2026; filed Jun 1, 2026.

Continue research

Keep researching A

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →